


Progression of Chronic Kidney Disease: Drivers of Disease and Opportunities for Earlier Diagnosis and Intervention



Burden of Chronic Kidney Disease in the US



Approximately **1 in 7** adults in the US are living with CKD^{1,*}




Overall life expectancy was shortened by 6 years with early CKD and by 16 years with CKD and comorbid T2D³


\$72 billion


CKD expenditure represents **25% of overall spending** for Medicare patients^{2,†}


Progressive Nature of Chronic Kidney Disease



Progression of CKD Increases the Risk for Adverse Outcomes⁶







eGFR (mL/min/1.73 m²)



Older adults with CKD are **6-fold more likely** to die from CV causes than develop ESKD^{7,#}

Event rate per 100 person-yr


eGFR and ACR are strong and independent predictors of CV mortality^{8,11}

*Prevalence of CKD in US adults using NHANES 2013-2016 data. CKD may be overestimated as persistence of albuminuria or creatinine was not accounted for based on KDIGO recommendations. *Based on 2017 data. *This data comes from a retrospective, observational cohort study (N=29,303) using administrative data in the Henry Ford Health System (HFHS). Outcomes for CKD progression included progression to a higher stage of CKD based on eGR and ESRD, defined as a composite outcome of CKD stage 5 (eGFR <15 mL/min), renal transplant or dialysis. *N=1,120,295. *Cardiovascular event was defined as hospitalization for coronary heart disease, heart dislure, ischemic stroke, and peripheral arterial disease. #Based on a cohort study including 1268 participants 65 years and older with eGFR <60. *In=24,777; 15 studies; 1879 cases of CV mortality.

ACR = albumin-to-creatinine ratio; CKD = chronic kidney disease; CV = cardiovascular; eGFR = estimated glomerular filtration rate; ESKD = end-stage kidney disease; GFR = glomerular filtration rate; T2D = type 2 diabetes; US = United States

Importance of Screening and Monitoring

CKD is classified based on GFR category and albuminuria category⁴



Monitoring of CKD Should Intensify as Renal Function Declines⁴

Recommended frequency of monitoring[®]

(number of times per year) by GFR and albuminuria category

			Persistent albuminuria categories		
			A1	A2	A3
			<30 mg/g <3 mg/mmol	30-300 mg/g 3-30 mg/mmol	>300 mg/g >30 mg/mmol
GFR categories (mL/min/1.73m²)	G1	>90	1/year if CKD		2/year
	G2	60-89			
	G3a	45-59	1/year	2/year	3/year
	G3b	30-44	2/year	3/year	5/year
	G4	15-29	3/year		4+/year
	G5	<15	4+/year		
			KDIGO recommends referral to a nephrologist for advanced CKD		


Diagnosis of CKD in Patients with T2D Needs Improvement¹

Only 1 in 10 adults with CKD are aware of their diagnosis


*Does not fulfill the criteria for CKD in the absence of evidence of kidney damage. *Relative to young adult level. *Including nephrotic syndrome (albumin excretion usually >2200 mg/24 hours [UACR >2220 mg/g; >220 mg/mmol]). *Patients were classified as fast progressors if they lost >4 mL/min/1.73 m² per year in eGFR in a large cohort of patients with mild-moderate CKD. *green = low risk (if no other markers of kidney disease, no CKD); yellow = moderately increased risk; orange = high risk; red = very high risk.

CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; GFR = glomerular filtration rate; KDIGO = Kidney Disease Improving Global Outcomes; T2D = type 2 diabetes; UACR = urine albumin-to-creatinine ratio


Diabetes as a Driver of Chronic Kidney Disease



In Patients with T2D, Early Stages of CKD are Most Prevalent¹³



Long-term Progression of Kidney Disease in Patients with T2D



*Age-standardized US prevalence of CKD by cause in 2016. 'Distribution of markers of CKD in NHANES participants with diabetes in 2013–2016. CKD defined as UACR \geq 30 mg/g or eGR <60 mL/min/1.73 m². 'In addition, UACR \geq 30 mg/g. 'Defined as urinary albumin concentration 5-20 mg/L. 'The UKPDS enrolled patients with newly diagnosed T2D. 'Defined as a urinary albumin concentration 0-299 mg/L. 'The Defined as a urinary albumin concentration 0-299 mg/L.'The Defined as a urinary albumin concentration 0-299 mg/L.'The Defined as a urinary album 0-275 mg/L.'The Defined as a urinary album 0-275 mg/L.'The Defined as a urinary album 0-275 mg/L.'The Defined as a urina

CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; ESKD = end-stage kidney disease; NHANES = National Health and Nutrition Examination Survey; T2D = type 2 diabetes; UACR = urine albumin-to-creatinine ratio; US = United States

Diabetes is the leading cause of ESKD²

In patients with T2D, CKD stages 1–3b combined are

10x more prevalent

than stage 4–5 combined¹³

In newly diagnosed patients with T2D...

38% Developed albuminuria[§]


28%

Developed eGFR <60 mL/min/1.73 m² (CKD stage 3–5)


over a median of **15 years**¹⁴

Current Approaches to Management

Targets for Therapeutic Intervention in CKD




Optimal Risk Factor Management Does Not Eliminate Risk of Diabetic Nephropathy^{21,22,†}



Residual Nephropathy Risk in Patients with T2D and Microalbuminuria Randomized

Conventional and intensive management based on treatment goals for BP, HbA1c, and cholesterol in the 1999 Steno-2 trial over a mean follow up of 3.8 years.

Potential Impact of Early Intervention to Maintain Renal Function²³



Guidelines Recommend Routine Screening for CKD in Patients with Cardiorenal-metabolic Disease

KDIGO^{4,24}

Regular testing of high-risk groups (including those with T2D, HTN, CVD) can give early indication of kidney damage. A team-based and integrated approach to manage these patients should focus on regular assessment, control of multiple risk factors, and self-management to protect kidney function and reduce risk of complications.

ADA⁹

Annually assess urinary albumin and eGFR in patients with T2D.

*This is not an exhaustive list of treatable risk factors. Diabetic nephropathy was defined as a urinary albumin excretion of more than 300 mg/24 hours in at least one of the two-yearly examinations.

ADA = American Diabetes Association; ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CKD = chronic kidney disease; CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c; HTN = hypertension; KDIGO = Kidney Disease Improving Global Outcomes; T2D = type 2 diabetes

Summary



Burden of CKD is Significant

- 1 in 7 adults in the US is living with CKD, and increases in the prevalence of CKD risk factors are anticipated to increase the burden of ESKD^{1,25}
- Progressive deteriorations in renal function increase the risk of adverse outcomes, such as risk of hospitalizations, CV events, mortality, and healthcare costs^{2,10}
- CKD significantly shortens life span which is further reduced with comorbid T2D³



Screen, Diagnose, and Manage Early

Several guidelines recommend to regularly screen patients at increased risk^{4,9}

- Roughly 10% of patients with CKD and T2D receive a diagnosis²⁶
- In patients with T2D, earlier stages (1–3) of CKD are more common than late stages¹³
- 35 45% of patients with CKD (stages 2 4) will progress to a worse stage of kidney disease within 5 years⁵



Monitor Renal Function

Engage patients in risk factor reduction and use multifactorial interventions to tailor treatment regimens to the individual

- KDIGO recommends routine CKD monitoring with increasing frequency as renal function declines⁴
- Lower eGFR and higher albuminuria are independently associated with increased adverse CV outcomes and premature death, which is worse in patients with T2D²⁷

References

1. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2019. 2. United States Renal Data System. 2019 Annual Data Report – Executive Summary. https://www.usrds.org/media/2371/2019-executive-summary.pdf. Accessed September 14, 2020. 3. Wen CP, Chang 2019. 2. United states Refin Data System. 2019 Annual Data Report – Executive Southinary, Industry, New Newson, Southinary, Industry, Data System. 2019 Annual Data Report – Executive Southinary, Industry, New Newson, Southinary, Industry, Data System. 2019 Annual Data Care. 2020;43(suppl 1):S1-S212. 10. Go AS, Yang J, Tan TC, et al. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. BMC Nephrol. 2018;19(1):146. 11. Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567-581. 12. United States Renal Data System. 2018 Annual Data Report – Chronic Kidney Disease (CKD) in the United States. https://www.usrds.org/2018/download/2018_Volume_1_CKD_ in_the_US.pdf. Accessed September 14, 2020. 13. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Dep Diabetes Res Care. 2016;4(1):e00154. 14. Retnakaran R, Cuil CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group, Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832-1839. 15. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (WRPDS Study Group, Risk factors for the Progression of Calibratic Construction) in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). (Kinge Int. 2003;63(1):225-232. 16. Ku E, Johansen KL, McCulloch CE, Time-Centered Approach to Understanding Risk Factors for the Progression of CKD. *Clin J Am Soc Nephrol*. 2018;13(5):693-701. 17. Kazancioğlu R. Risk factors for chronic kidney disease: an update. *Kidney Int Suppl* (2011). 2013;3(4):368-371. 18. Khan YH, Sarriff A, Adnan AS, Khan AH, Mallhi TH. Chronic Kidney Disease, Huid Overload and Diuretics: A Complicated Triangle, *PLoS One*, 2016;11(7):e0159335. **19**, Sandilands EA, Dhaun N, Dear JW, Webb DJ, Measurement of renal function in patients with chronic kidney disease. *J Clin Pharmacol*. 2013;76(4):504-515. **20**. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review, *JAMA*. 2019;322(13):1294-1304. **21**. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. *Nat Rev Endocrinol*. 2010;6(1):19-25. **22**. Geade P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial interventine with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *Lancet*. 1999;353(9153):617-622. **23**. Gasevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. *J Am Soc Nephrol*. 2009;20(3):465-468. **24**. de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. *Kidney Int*. 2020;98(4):839-848. **25**. McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. Projecting ESRD Incidence and Prevalence in the United States through 2030. *J Am Soc Nephrol*. 2010;20(3):417-424. **24**. Devent DC Churden detection of detection of characteria distribution of a distribution of the advance in the United States through 2030. *J Am Soc Nephrol*. 2010;20(3):417-424. **24**. Devent DC Churden detection of characteria distribution detection of detection and Prevalence in the United States through 2030. *J Am Soc Nephrol*. 2010;20(3):457-468. **24**. Devent DC Churden detection of characteria distribution to a distribution to a DC Characteria detection of characteria distribution detection and Drevalence in the United States through 2030. *J Am Soc Nephrol*. 2010;20(3):457-468. **24**. Devent DC Churden detection of characteria distribution detection and Drevalence in the United States through 2030. *J Am Soc Nephrol*. 2010;20(4):454. 456. Devent DC Characteria detection and 2019;30(1):127-135. **26**. Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). *PLoS One.* 2014;9(11):e110535. **27**. Fox CS, Matsushita K, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis [published ahead of print September 24, 2012]. Lancet. 2012;380(9854):1662-1673. Erratum in: Lancet. 2013;381(9864):374.



CKD = chronic kidney disease; CV = cardiovascular; eGFR = estimated glomerular filtration rate; ESKD = end-stage kidney disease; KDIGO = Kidney Disease Improving Global Outcomes; T2D = type 2 diabetes

©2020 AstraZeneca, All rights reserved, US-US-44981 Last Updated 12/20